The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Drugs Five Years Later: Acyclovir
Abstract
In the 5 years since its release for clinical use, acyclovir (9-[2-hydroxyethoxymethyl]guanine) has proved to be a safe and effective agent for therapy of herpes simplex and varicella-zoster infections. The drug's availability in topical, oral, and intravenous preparations has allowed its use in a range of clinical situations. Acyclovir must be phosphorylated by viral thymidine kinase in infected cells, where it then acts to inhibit viral DNA replication specifically. Epstein-Barr virus and human cytomegalovirus infections do not seem to respond to acyclovir therapy, although in-vitro effects on these viruses may be seen. Acyclovir is well absorbed and distributed, with cerebrospinal fluid levels 50% that of plasma. Clearance is almost entirely by the renal route, with a half-life of 20 hours in the anuric patient. Acyclovir has an excellent safety profile, its major adverse effect being transient serum creatinine elevations during high-dose intravenous use. Major uses include treatment of primary and recurrent genital herpes and herpes encephalitis and prophyllaxis and therapy of mucocutaneous herpes and varicella-zoster infections in immunocompromised patients. Resistance to acyclovir in herpes simplex virus is rarely encountered and does not seem to be due to long-term chronic suppressive therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vidarabine versus Acyclovir Therapy in Herpes Simplex Encephalitis
Whitley, R. J., Alford, C. A., Hirsch, M. S., Schooley, R. T., Luby, J. P., Aoki, F. Y., Hanley, D., Nahmias, A. J., Soong, S.-J., & The NIAID Collaborative Antiviral Study Group* (1986) · New England Journal of Medicine · doi:10.1056/nejm198601163140303 · Cited by 896
ACYCLOVIR VERSUS VIDARABINE IN HERPES SIMPLEX ENCEPHALITIS
Sköldenberg, B., Alestig, K., Burman, L., Forkman, A., Lövgren, K., Norrby, R., Stiernstedt, G., Forsgren, M., Bergström, T., Dahlqvist, E., et al. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92623-0 · Cited by 610
Cited by
A Controlled Trial Comparing Vidarabine with Acyclovir in Neonatal Herpes Simplex Virus Infection
Whitley, R., Arvin, A., Prober, C., Burchett, S., Corey, L., Powell, D., Plotkin, S., Starr, S., Alford, C., Connor, J., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199102143240703 · Cited by 388
OʼBrien, J. J., & Campoli-Richards, D. M. (1989) · Drugs · doi:10.2165/00003495-198937030-00002 · Cited by 363
Underdiagnosis of Genital Herpes by Current Clinical and Viral-Isolation Procedures
Koutsky, L. A., Stevens, C. E., Holmes, K. K., Ashley, R. L., Kiviat, N. B., Critchlow, C. W., & Corey, L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206043262305 · Cited by 286
Metadata
- Authors
- DORSKY, D. I., & CRUMPACKER, C. S.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1987-12-01
- Volume
- 107
- Issue
- 6
- Pages
- 859-874
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2047415999
- Cited by
- 162
- References
- 2
- FWCI
- 11.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drugs Five Years Later: Acyclovir. https://app.cochat.ai/papers/10.7326/0003-4819-107-6-859
- The paper
- DORSKY, D. I., & CRUMPACKER, C. S. (1987). Drugs Five Years Later: Acyclovir. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-107-6-859
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.